tbuckley/cabot-search huggingface dataset:
On the origin of the low immunogenicity and biosafety of a neutral α-helical polypeptide as an alternative to polyethylene glycol
Authors: Jialing Sun, Junyi Chen, Yiming Sun, Yingqin Hou, Zhibo Liu, Hua Lu
Journal: Bioactive Materials (2023)

Poly(ethylene glycol) (PEG) is a prominent synthetic polymer widely used in biomedicine. Despite its notable success, recent clinical evidence highlights concerns regarding the immunogenicity and adverse effects associated with PEG in PEGylated proteins and lipid nanoparticles. Previous studies have found a neutral helical polypeptide poly(γ-(2-(2-(2-methoxyethoxy)ethoxy)ethyl l-glutamate), namely L-P(EG3Glu), as a potential alternative to PEG, displaying lower immunogenicity. To comprehensively assess the immunogenicity, distribution, degradation, and biosafety of L-P(EG3Glu), herein, we employ assays including enzyme-linked immunosorbent assay, positron emission tomography-computed tomography, and fluorescent resonance energy transfer. Our investigations involve in vivo immune responses, biodistribution, and macrophage activation of interferon (IFN) conjugates tethered with helical L-P(EG3Glu) (L20k-IFN), random-coiled DL-P(EG3Glu) (DL20k-IFN), and PEG (PEG20k-IFN). Key findings encompass: minimal anti-IFN and anti-polymer antibodies elicited by L20k-IFN; length-dependent affinity of PEG to anti-PEG antibodies; accelerated clearance of DL20k-IFN and PEG20k-IFN linked to anti-IFN and anti-polymer IgG; complement activation for DL20k-IFN and PEG20k-IFN but not L20k-IFN; differential clearance with L20k-IFN kidney-based, and DL20k-IFN/PEG20k-IFN accumulation mainly in liver/spleen; enhanced macrophage activation by DL20k-IFN and PEG20k-IFN; L-P(EG3Glu) resistance to proteolysis; and safer repeated administrations of L-P(EG3Glu) in rats. Overall, this study offers comprehensive insights into the lower immunogenicity of L-P(EG3Glu) compared to DL-P(EG3Glu) and PEG, supporting its potential clinical use in protein conjugation and nanomedicines.
When I use a word . . . Medicines regulation and royal college charters
Authors: Jeffrey K Aronson
Journal: BMJ (2023)

“Charter” was originally a term used to describe a piece of paper or parchment on which something was written. However, the word later came to be used to describe any document that created or empowered a body or institution, or its contents, listing the powers and privileges that it endowed. Royal charters between 1540 and 1691 gave physicians the power to regulate the quality of medicines issued by others, typically apothecaries. The monarchs who issued them—Henry VIII (1540), James VI of Scotland (1599), Charles II (1681), and William and Mary (1691)—respectively relating to medical colleges in London, Glasgow, Edinburgh, and Dublin, appreciated the importance of regulation by physicians of the quality of medicines that others, typically apothecaries, purveyed.
Evolutionary Insights from a Large-Scale Survey of Population-Genomic Variation
Authors: Zhiqiang Ye, Wen Wei, Michael E Pfrender, Michael Lynch
Journal: Molecular Biology and Evolution (2023)

Abstract The field of genomics has ushered in new methods for studying molecular-genetic variation in natural populations. However, most population-genomic studies still rely on small sample sizes (typically, &amp;lt;100 individuals) from single time points, leaving considerable uncertainties with respect to the behavior of relatively young (and rare) alleles and, owing to the large sampling variance of measures of variation, to the specific gene targets of unusually strong selection. Genomic sequences of ∼1,700 haplotypes distributed over a 10-year period from a natural population of the microcrustacean Daphnia pulex reveal evolutionary-genomic features at a refined scale, including previously hidden information on the behavior of rare alleles predicted by recent theory. Background selection, resulting from the recurrent introduction of deleterious alleles, appears to strongly influence the dynamics of neutral alleles, inducing indirect negative selection on rare variants and positive selection on common variants. Temporally fluctuating selection increases the persistence of nonsynonymous alleles with intermediate frequencies, while reducing standing levels of variation at linked silent sites. Combined with the results from an equally large metapopulation survey of the study species, classes of genes that are under strong positive selection can now be confidently identified in this key model organism. Most notable among rapidly evolving Daphnia genes are those associated with ribosomes, mitochondrial functions, sensory systems, and lifespan determination.
Human chemically-derived hepatic progenitors (hCdHs) as a source of liver organoid generation: Application in regenerative medicine, disease modeling, and toxicology testing
Authors: Soraya Salas-Silva, Yohan Kim, Tae Hun Kim, Myounghoi Kim, Daekwan Seo, Jeonghoon Choi, Valentina M. Factor, Haeng Ran Seo, Yeonhwa Song, Gyu Sung Choi, Yun Kyung Jung, Kungsik Kim, Kyeong Geun Lee, Jaemin Jeong, Ji Hyun Shin, Dongho Choi
Journal: Biomaterials (2023)

Several types of human stem cells from embryonic (ESCs) and induced pluripotent (iPSCs) to adult tissue-specific stem cells are commonly used to generate 3D liver organoids for modeling tissue physiology and disease. We have recently established a protocol for direct conversion of primary human hepatocytes (hPHs) from healthy donor livers into bipotent progenitor cells (hCdHs). Here we extended this culture system to generate hCdH-derived liver organoids for diverse biomedical applications.
Palliative Care in Adolescents and Young Adults With Cancer
Authors: Emily E. Johnston, Abby R. Rosenberg
Journal: Journal of Clinical Oncology (2023)

Palliative care (PC) aims to improve quality of life (QOL) for patients with serious illness and their families by recognizing and alleviating the physical, emotional, social, existential, and spiritual suffering of patients and their communities. Because adolescents and young adults (AYAs, age 15-39 years) with cancer commonly report distress across all these domains and because that distress translates to their QOL during and after their cancers, PC is particularly relevant for this population. Here, we review the evidence for PC among AYAs with cancer, including its rationale, gaps, opportunities, and implications for care delivery. For example, nearly 90% of AYAs with cancer report distressing symptoms during their treatment, those who survive report ongoing unmet psychosocial and physical health needs, and those who die from their cancers are highly likely to receive medically intense care that is discordant with their goals and values. AYA communication and decision making can be challenging because of ethical and developmental considerations regarding the patient's autonomy and competing priorities of patients and caregivers. PC interventions (including primary PC delivered by oncologists, routine PC subspecialty care, symptom tracking, advance care planning, and psychosocial programs promoting AYA resilience) are all associated with improved patient-centered outcomes. However, PC is inconsistently integrated into AYA oncology care, and access to PC programs is not equitable; marginalized groups continue to experience poorer outcomes. Ongoing and future research and clinical initiatives must continue to bridge these gaps. Improving the QOL of AYAs with cancer is a shared goal of the larger clinical oncology community, and including PC in AYA cancer care delivery can help attain that goal.
Regulation of Pain Perception by Microbiota in Parkinson Disease
Authors: Zulmary Manjarres, Margarita Calvo, Rodrigo Pacheco
Journal: Pharmacological Reviews (2023)

Pain perception involves current stimulation in peripheral nociceptive nerves and the subsequent stimulation of postsynaptic excitatory neurons in the spinal cord. Importantly, in chronic pain, the neural activity of both peripheral nociceptors and postsynaptic neurons in the central nervous system is influenced by several inflammatory mediators produced by the immune system. Growing evidence has indicated that the commensal microbiota plays an active role in regulating pain perception by either acting directly on nociceptors or indirectly through the modulation of the inflammatory activity on immune cells. This symbiotic relationship is mediated by soluble bacterial mediators or intrinsic structural components of bacteria that act on eukaryotic cells, including neurons, microglia, astrocytes, macrophages, T cells, enterochromaffin cells, and enteric glial cells. The molecular mechanisms involve bacterial molecules that act directly on neurons, affecting their excitability, or indirectly on non-neuronal cells, inducing changes in the production of proinflammatory or anti-inflammatory mediators. Importantly, Parkinson disease, a neurodegenerative and inflammatory disorder that affects mainly the dopaminergic neurons implicated in the control of voluntary movements, involves not only a motor decline but also nonmotor symptomatology, including chronic pain. Of note, several recent studies have shown that Parkinson disease involves a dysbiosis in the composition of the gut microbiota. In this review, we first summarize, integrate, and classify the molecular mechanisms implicated in the microbiota-mediated regulation of chronic pain. Second, we analyze the changes on the commensal microbiota associated to Parkinson disease and propose how these changes affect the development of chronic pain in this pathology. SIGNIFICANCE STATEMENT: The microbiota regulates chronic pain through the action of bacterial signals into two main locations: the peripheral nociceptors and the postsynaptic excitatory neurons in the spinal cord. The dysbiosis associated to Parkinson disease reveals increased representation of commensals that potentially exacerbate chronic pain and reduced levels of bacteria with beneficial effects on pain. This review encourages further research to better understand the signals involved in bacteria-bacteria and bacteria-host communication to get the clues for the development of probiotics with therapeutic potential.
Letter to the Editor: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect or residual confounding?
Authors: Edo J. Dongelmans, Milan J. Sonneveld, Harry L.A. Janssen
Journal: Hepatology (2023)

1Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands 2Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Canada List of abbreviations: NA, nucleo(s)tide analogue. Correspondence Harry L.A. Janssen, Erasmus MC Transplant Institute, Department of Gastroenterology and Hepatology, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Email: [email protected]
New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease
Authors: Luis Antonio Diaz, Gerald Scott Winder, Lorenzo Leggio, Jasmohan S. Bajaj, Ramon Bataller, Juan Pablo Arab
Journal: Hepatology (2023)

Alcohol use disorder remains a significant public health concern, affecting around 5% of adults worldwide. Novel pathways of damage have been described during the last years, providing insight into the mechanism of injury due to alcohol misuse beyond the direct effect of ethanol byproducts on the liver parenchyma and neurobehavioral mechanisms. Thus, the gut-liver-brain axis and immune system involvement could be therapeutic targets for alcohol use disorder. In particular, changes in gut microbiota composition and function, and bile acid homeostasis, have been shown with alcohol consumption and cessation. Alcohol can also directly disrupt intestinal and blood-brain barriers. Activation of the immune system can be triggered by intestinal barrier dysfunction and translocation of bacteria, pathogen-associated molecular patterns (such as lipopolysaccharide), cytokines, and damage-associated molecular patterns. These factors, in turn, promote liver and brain inflammation and the progression of liver fibrosis. Other involved mechanisms include oxidative stress, apoptosis, autophagy, and the release of extracellular vesicles and miRNA from hepatocytes. Potential therapeutic targets include gut microbiota (probiotics and fecal microbiota transplantation), neuroinflammatory pathways, as well as neuroendocrine pathways, for example, the ghrelin system (ghrelin receptor blockade), incretin mimetics (glucagon-like peptide-1 analogs), and the mineralocorticoid receptor system (spironolactone). In addition, support with psychological and behavioral treatments is essential to address the multiple dimensions of alcohol use disorder. In the future, a personalized approach considering these novel targets can contribute to significantly decreasing the alcohol-associated burden of disease.
Reply: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect, or residual confounding?
Authors: Yun-Fan Liaw, Wen-Juei Jeng, Rong-Nan Chien
Journal: Hepatology (2023)

1College of Medicine, Chang Gung University, Taipei, Taiwan 2Liver Research Unit, Chang Gung Memorial Hospital, Taiwan 3Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou medical center, Taoyuan, Taiwan Disclosures: The authors have no financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Correspondence Yun-Fan Liaw, Liver Research Unit, Chang Gung Memorial Hospital, 199, Tung Hwa North Road, Taipei, 105, Taiwan. Email: [email protected]
Single-cell transcriptomes reveal the heterogeneity and microenvironment of vestibular schwannoma
Authors: Zirong Huo, Zhaohui Wang, Huahong Luo, Dilihumaer Maimaitiming, Tao Yang, Huihui Liu, Huipeng Li, Hao Wu, Zhihua Zhang
Journal: Neuro-Oncology (2023)

Vestibular schwannoma (VS) is the most common benign tumor in the cerebellopontine angle and internal auditory canal. Illustrating the heterogeneous cellular components of VS could provide insights into its various growth patterns.
Clinical landscape of TP73 structural variants in ATL patients
Authors: Hiroaki Hiramatsu, Rui Yokomori, Liu Shengyi, Norio Tanaka, Seiichi Mori, Kazuma Kiyotani, Osamu Gotoh, Shigeru Kusumoto, Nobuaki Nakano, Youko Suehiro, Asahi Ito, Ilseung Choi, Eiichi Ohtsuka, Michihiro Hidaka, Kisato Nosaka, Makoto Yoshimitsu, Yoshitaka Imaizumi, Shinsuke Iida, Atae Utsunomiya, Tetsuo Noda, Hiroyoshi Nishikawa, Ryuzo Ueda, Takaomi Sanda, Takashi Ishida
Journal: Leukemia (2023)

TP73, a TP53 family member, is involved in the pathogenesis of adult T-cell leukemia/lymphoma (ATL) and is regulated by the intragenic super-enhancer [1,2].We have reported that TP73 structural variants (SVs) with deletion of exons 2-3, which were potentially associated with the formation of super-enhancer, were present in a fraction of ATL patients.Experimental deletion of exons 2-3 conferred a competitive advantage to ATL cells by promoting their proliferation [2].Hence, following this observation, here we explored the clinical landscape of TP73 SVs in ATL patients.Study subjects were mogamulizumab-naïve ATL patients without prior allogeneic hematopoietic stem cell transplantation, who then received mogamulizumab-containing treatment (n = 63) [3].They had all been enrolled in our previous study [4].DNA/RNA preparation for genomic analysis, exome library preparation and sequencing, RNA-sequencing, somatic variant call, fusion gene detection using RNA-sequencing, detection of SVs in the 3′-UTR of CD274 gene, HLA alteration call, and statistical analyses were all as previously described [4].Tumor purity for tumor-derived DNA was calculated by Control-FREEC [5].TP73 SVs, of exons 2 or 2-3 deletion, were evaluated by three different programs, such as DeviCNV v1.5.1 (Rhelixa Inc., Tokyo, Japan) [6], Manta v1.6.0, and GRIDSS2 v2.13.2, using our previous exome dataset [4].The presence of TP73 SVs was defined when they were detected by at least one of these three programs.In the cases where TP73 SVs were identified by any of these programs, the original sequence data were manually investigated to confirm the presence of TP73 SVs.The current study was approved by the institutional review boards at all participating sites, and all patients provided written informed consent before blood or tissue sampling.
346P Quality of life (QoL) and toxicity in patients (pts) with hormone receptor-positive, HER2-negative early breast cancer (HR+, HER2– eBC) treated with adjuvant (adj) endocrine therapy (ET) in the CANcer TOxicities (CANTO) study
Authors: A. Bertaut, T. Badovinac Crnjevic, A-L. Martin, C. Gaudin, L. Chen
Journal: Annals of Oncology (2023)
495P Prognostic value of PIK3CA mutational status in tissue &amp; plasma in HR+/HER2- breast cancer (BC)
Authors: R. Lozano Mejorada, E. Terán Brage, J.A. Muñoz León, Á. López Gutiérrez, L. Figuero Pérez, A. Rodrígues Francoso, R. Seijas Tamayo, D. Morchón Araujo, M.D.C. Garijo Martínez, J. Roldán-Ruiz, M.M. Abad Hernández, M. Sancho de Salas, E. Fonseca Sánchez, C.A. Rodríguez Sánchez
Journal: Annals of Oncology (2023)
345P The effect of early post-operative exercise on shoulder function in breast cancer patients: A randomised controlled trial
Authors: J. Min, J. Ryu, S. Yeon, S. Park, J.Y. Kim, S.I. Kim, J.W. Kang, S. Jun, R. Park, Y.J. Lee, T.H. Lee, E. Kim, C. Oh, K. Chiho, D-H. Park, J. Jeon
Journal: Annals of Oncology (2023)
2406P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma of the penis: Subgroup analysis of the PEVOsq basket trial
Authors: E. Coquan, C.A. Gomez-Roca, A. Lambert, B. You, D. Vansteene, F. Bigot, S. Cousin, Z. Castel Ajgal, E. Jeannot, E. Guerini Rocco, G. Frige, L. Mazzarella, M. Francisco, N. Servant, M. Halladjian, M. Kamal, F. Legrand, M. Jimenez, B. Cabarrou, C. Le Tourneau
Journal: Annals of Oncology (2023)
341P Impact of environmental temperature on clinical outcomes of early-stage breast cancer (BC)
Authors: A.M. Roy, A. George, K. Attwood, A. Gupta, B. Czerniecki, J. Carpten, V.F. Borges, B. Schneider, J. Kolesar, C. Moskaluk, C. Shriver, C. Matsen, S. Ganesan, S. Phadke, W. Razaq, S. Gandhi
Journal: Annals of Oncology (2023)
349P The influence of diabetes on taxane-induced neurotoxicity and quality of life in breast cancer patients
Authors: E. Cimbro, M. Dessi, P. Ziranu, C. Madeddu, F. Atzori, E. Lai, A. Pretta, S. Mariani, C. Donisi, D. Spanu, M. Pozzari, S. Murgia, C. Codipietro, E. Palmas, G. Sanna, F. Semonella, S. Sardo, G. Finco, M. Scartozzi
Journal: Annals of Oncology (2023)
339P An online mindfulness-based stress-reduction (MBSR) intervention for breast cancer (BC) survivors: A randomized trial
Authors: M.G. Salazar-Alejo, A.S. Ferrigno, J. Gutiérrez-Ornelas, F. Mesa-Chavez, A. Platas, H.C. Verduzco-Aguirre, C.M. Villarreal Garza
Journal: Annals of Oncology (2023)
343P Modulation of the immune system (ImS) during moderate physical activity (mPA) in breast cancer (BC) patients (pts) treated with neoadjuvant chemotherapy (NACT)
Authors: O. Garrone, A. Abbona, M. Paccagnella, F. Ruatta, P. Vanella, G. Tomasello, F. Barbin, M.G. Rossino, N. Croce, M.C. Merlano
Journal: Annals of Oncology (2023)
2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)
Authors: S. Sridhar, P.H. O'Donnell, T.W. Flaig, J.E. Rosenberg, C.J. Hoimes, M.I. Milowsky, S. Srinivas, S. George, R.R. McKay, D.P. Petrylak, P.M. Coelho Barata, C. Hwang, M. Cruz-Correa, M. Iafolla, M. Mckean, R. Dreicer, S. Brancato, J.J. Lukas, Y. Yu, H. Moon
Journal: Annals of Oncology (2023)
2370P Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Authors: A. Bottiglieri, W. Ferrari Bravo, A. Rametta, L. Provenzano, D. Raggi, L. Marandino, E. Farè, V. Longo, V. Guadalupi, M. Stellato, E. Verzoni, P. Sepe, M. Claps, G. Calareso, A. Alessi, L. Cattaneo, M. Colecchia, G. Procopio, A. Necchi, P. Giannatempo
Journal: Annals of Oncology (2023)
2374P A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Authors: P. Grivas, S. Sridhar, B. Perez Valderrama, D.E. Castellano Gauna, Y. Loriot, B. Doger de Spéville, D. Pouessel, M.S. van der Heijden, M.D. Galsky, S. Gulati, A. Ravaud, E. Fontana, A.I. Spira, B.A. Gartrell, A. Mortazavi, N. Isambert, D. Baxter, T.B. Powles, A.H. Khaled, R. Morales Barrera
Journal: Annals of Oncology (2023)
2375P Neoadjuvant sintilimab combined with gemcitabine and cisplatin (GP) for muscle-invasive bladder cancer (MIBC) patients followed by selective bladder sparing surgery
Authors: Z. Tong, G. Fu, F. Zhou, X. Liu, X. Xue, H. Zhang, Y. Wang, X. Zhu, Y. Gao, L. Liu, X. Bao, Y. Zheng, W. Fang, P. Zhao, B. Jin
Journal: Annals of Oncology (2023)
2366P Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
Authors: D.E. Castellano Gauna, I. Duran Martinez, B. Mellado Gonzalez, M.A. Climent Duran, X. Garcia Del Muro, N. Sala González, T. Alonso Gordoa, E. Sevillano Fernandez, M. Domenech Santasusana, J. Paramio, F.X. Real, N. Malats, A. Font Pous
Journal: Annals of Oncology (2023)
2368P Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Authors: P. Giannatempo, A. Bottiglieri, V. Guadalupi, L. Marandino, D. Raggi, M. Stellato, A. Rametta, G. Baciarello, P. Sepe, M. Claps, S. Buti, S. Pipitone, R. Iacovelli, G. Calareso, A. Alessi, L. Cattaneo, E. Verzoni, C. Ortega, G. Procopio, A. Necchi
Journal: Annals of Oncology (2023)
2367P A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Authors: R. Pachynski, G. Chatta, R.K. Jain, H. Moon, R. Sweis, S. Delacroix, T. Fang, S.P. Fling, A. Lacroix, J. Kaiser, E. Sharon, E. Yu
Journal: Annals of Oncology (2023)
2369P Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
Authors: B.A. McGregor, M.T. Campbell, J. Huang, W. Xie, M.A. Bilen, A. Mortazavi, P. Ravi, A. Shah, D. Einstein, G.P. Sonpavde, R.R. McKay, A.O. Siefker-Radtke, J. Bellmunt, T.K. Choueiri
Journal: Annals of Oncology (2023)
2372P Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
Authors: M-O. Grimm, M. Schostak, C.B. Grün, W.C. Loidl, M. Pichler, U. Zimmermann, B.J. Schmitz-Dräger, T. Steiner, F. Roghmann, G. Niegisch, M. Schmitz, G. Baretton, K. Leucht, U. Schumacher, S. Foller, F. Zengerling, J. Meran
Journal: Annals of Oncology (2023)
2364MO Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial
Authors: C. Thibault, M. Bennamoun, A. Flechon, G. Gravis, D. Pouessel, P-F. Combe, D. Borchiellini, Y. Loriot, B. Laguerre, P. Barthelemy, M. Gross Goupil, C. Helissey, O. Huillard, M. Cancel, L. Campedel, F. Audenet, H. Belhouari, S. Kotti, Y. Tran, S. Oudard
Journal: Annals of Oncology (2023)
2373P Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361
Authors: R. Mamtani, N. Matsubara, A. Montesa Pino, U. Anido Herranz, M.A.N. Sendur, G. Gravis, O. Huillard, H.J. Lee, R. Gafanov, F. Joly Lobbedez, J. Bedke, A. Sella, Y.H. Chang, K. Imai, B. Homet Moreno, J. Xu, A. Alva, T.B. Powles
Journal: Annals of Oncology (2023)